is tirzepatide going away Side Effects: What to Expect (and When to Worry) Tirzepatide (Zepbound) for weight loss

130 mg/26 mL (5 mg/mL) solution in a single-dose vial for IV use (all three presentations approved as interchangeable) Recommended dosage is based on indication, patient age and body weight Starjemza will be available from Bio-Thera/Hikma with launch time frame TBD June 3, 2025 darolutamide (Nubeqa) Bayer

The request is not for the continuation of therapy, and

We use DEXA body composition scanning to track actual fat loss versus musclebecause executives who rely on metrics in the boardroom deserve the same precision in their health

Key Takeaways on Wegovy Insurance Coverage FDA-approved for weight management : Wegovy (semaglutide 2.4mg) is approved for chronic weight management in adults with BMI 30, or BMI 27 with at least one weight-related comorbidity Commercial insurance coverage is expanding : About 40-50% of employer-sponsored plans now cover GLP-1 medications for weight loss, up from under 20% in 2023 Medicare does NOT cover Wegovy for weight loss : Federal law prohibits Medicare Part D from covering drugs prescribed solely for weight management no exceptions List price without insurance : Approximately $1,349/month ($16,188/year) at retail pharmacy Savings programs available : Novo Nordisk offers a savings card reducing cost to as low as $0-$25/month for eligible commercially insured patients Wegovy is a once-weekly injectable prescription medication containing semaglutide at the 2.4mg dose, manufactured by Novo Nordisk